Patent intelligence · US
US 11583530
Compounds for the prevention and treatment of medical disorders and uses thereof
Compounds for the prevention and treatment of medical disorders and uses thereof
Patent details — US 11583530
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 21, 2023
- Expiration
- Feb 16, 2043
- Applicant
- Galectin Sciences, LLC
- Claims
- 29
- CPC classes
- A61K, A61K31/519, A61K45/06, A61P
Quick answer
US 11583530 (Compounds for the prevention and treatment of medical disorders and uses thereof) is held by Galectin Sciences, LLC. Status: granted. Granted Feb 21, 2023. Expires Feb 16, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Galectin Sciences, LLC
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/519, A61K45/06, A61P, A61P1/16, A61P11/06
More from Galectin Sciences, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12377102
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11576924
Compounds for the prevention and treatment of diseases and the use thereof
granted -
US 11413303
Methods for treatment of arthritis
granted -
US 10799525
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 10744154
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
granted -
US 10420793
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 9974802
Composition of novel carbohydrate drug for treatment of human diseases
granted
Frequently asked questions
What is US patent 11583530?
US 11583530 (Compounds for the prevention and treatment of medical disorders and uses thereof) is held by Galectin Sciences, LLC. Status: granted. Granted Feb 21, 2023. Expires Feb 16, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11583530?
Galectin Sciences, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 11583530 expire?
Our index shows an expiration date of Feb 16, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.